{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:54:16Z","timestamp":1781067256163,"version":"3.54.1"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A study was performed to derive susceptibility testing interpretive breakpoints for doxycycline with\n            <jats:named-content content-type=\"genus-species\">Streptococcus pneumoniae<\/jats:named-content>\n            and to reassess breakpoints for tetracycline using the requirements defined in Clinical and Laboratory Standards Institute (CLSI) document M23-A3. Tetracycline and doxycycline MICs and disk diffusion zone sizes were determined on 189 isolates selected from the 2009-2010 CDC Active Bacterial Core surveillance strain collection according to the testing methods described in CLSI documents M07-A8 and M02-A10. Tetracycline and doxycycline MICs and zones were compared to each other directly, and the reproducibility of MICs and zone diameters for both drugs was determined. Scattergrams of tetracycline MICs versus corresponding zone diameters and doxycycline MICs versus zones were prepared, and analysis indicated that the present CLSI tetracycline MIC and disk breakpoints did not fit the susceptibility data for doxycycline. Doxycycline was 1 to 3 dilutions more potent than tetracycline, especially in strains harboring the\n            <jats:italic>tetM<\/jats:italic>\n            resistance determinant.\n            <jats:italic>tetM<\/jats:italic>\n            was detected in \u226590% of isolates having tetracycline MICs of \u22654 \u03bcg\/ml and in \u226590% with doxycycline MICs of \u22651. Limited pharmacokinetic\/pharmacodynamic (PK\/PD) data coupled with application of the error-rate bounded method of analysis suggested doxycycline-susceptible breakpoints of either \u22640.25 \u03bcg\/ml or \u22640.5 \u03bcg\/ml, with intermediate and resistant breakpoints 1 and 2 dilutions higher, respectively. The disk diffusion zone diameter correlates were susceptible at \u226528 mm, intermediate at 25 to 27 mm, and resistant at \u226424 mm. Revised lower tetracycline MIC breakpoints were suggested as susceptible at \u22641 \u03bcg\/ml, intermediate at 2 \u03bcg\/ml, and resistant at \u22654 \u03bcg\/ml. Suggested tetracycline disk diffusion zones were identical to those of doxycycline.\n          <\/jats:p>","DOI":"10.1128\/jcm.00125-13","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T06:34:49Z","timestamp":1365057289000},"page":"1798-1802","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Development of Doxycycline MIC and Disk Diffusion Interpretive Breakpoints and Revision of Tetracycline Breakpoints for Streptococcus pneumoniae"],"prefix":"10.1128","volume":"51","author":[{"given":"Steven D.","family":"Dallas","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Sciences, University of Texas Health Science Center, San Antonio, Texas, USA"},{"name":"Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"McGee","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Limbago","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Office of the Director, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Leticia","family":"McElmeel","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letitia C.","family":"Fulcher","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lonsway","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"e_1_3_2_3_2","volume-title":"Twenty-second informational supplement, M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement, M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_4_2","volume-title":"Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother","author":"Christianson J","year":"2001","unstructured":"ChristiansonJ AndesD CraigWA. 2001. Characterization of the pharmacodynamics of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model, abstr A-1103. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-302X.1995.tb00124.x"},{"key":"e_1_3_2_6_2","volume-title":"Abstr. 39th Annu. Meet. Infect. Dis. Soc. Am","author":"Christianson J","year":"2001","unstructured":"ChristiansonJ AndesD CraigWA. 2001. Magnitude of the 24-H AUC\/MIC required for efficacy of doxycycline (DOXY) against Streptococcus pneumoniae (SP) in a murine thigh-infection model, abstr 475. Abstr. 39th Annu. Meet. Infect. Dis. Soc. Am."},{"key":"e_1_3_2_7_2","volume-title":"Approved standard","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed, M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"8"},{"key":"e_1_3_2_8_2","volume-title":"Performance standards for antimicrobial disk susceptibility tests; approved standard\u201410th ed, M02-A10","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disk susceptibility tests; approved standard\u201410th ed, M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(92)90037-T"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/130.6.588"},{"key":"e_1_3_2_11_2","volume-title":"Approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing interpretive criteria and quality control parameters. Approved guideline, 3rd ed, M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_12_2","volume-title":"Twenty-third informational supplement, M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing. Twenty-third informational supplement, M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit017"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00125-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00125-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T20:41:49Z","timestamp":1646426509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00125-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1128\/JCM.00125-13"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00125-13","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"2013-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}